Summary
The aim of these studies was to compare the pharmacokinetics, pharmacodynamics, counterregulatory hormone and symptom responses, as well as cognitive function during hypoglycaemia induced by s. c. injection of 0.15 IU/kg of regular human insulin (HI) and the monomeric insulin analogue [Lys(B28),Pro (B29)] (MI) in insulin-dependent-diabetic (IDDM) subjects. In these studies glucose was infused whenever needed to prevent decreases in plasma glucose below 3 mmol/l. After MI, plasma insulin increased earlier to a peak (60 vs 90 min) which was greater than after HI (294±24 vs 255±24 pmol/l), and plasma glucose decreased earlier to a 3 mmol/l plateau (60 vs 120 min) (p<0.05). The amount of glucose infused to prevent plasma glucose falling below 3 mmol/l was ∼three times greater after MI than HI (293±26 vs 90±25 μmol · kg−1 · 60–375 min−1, p<0.05). After MI, hepatic glucose production was more suppressed (0.7±1 vs 5.9±0.54 μmol · kg−1 · min−1) and glucose utilization was less suppressed than after HI (11.6±0.65 vs 9.1±0.11μmol · kg−1 · min−1) (p<0.05). Similarly, plasma NEFA, glycerol, and β-OH-butyrate were more suppressed after MI than HI (p<0.05), whereas plasma lactate increased only after MI, but not after HI. Responses of counterregulatory hormones, symptoms and deterioration in cognitive function during plasma glucose plateau of 3 mmol/l were superimposable after MI and HI (p=NS). Post-hypoglycaemia hyperglycaemia was greater after MI than HI (at 480 min 12.1±1 vs 11±1 mmol/l) because of greater hepatic glucose production during insulin waning which occurred at least 135 min earlier with MI as compared to HI (p<0.05). It is concluded that counterregulatory hormones, symptoms and deterioration in cognitive function during hypoglycaemia respond similarly after MI and HI. The biological effect of MI appears greater than that of HI for at least 4 h after the s.c. injection and appears as a good candidate for achieving optimal post-prandial glucose control in IDDM.
Article PDF
Similar content being viewed by others
Abbreviations
- HI:
-
Human insulin
- MI:
-
monomeric insulin
- NEFA:
-
non-esterified fatty acid
- HGO:
-
hepatic glucose production rate
- β-OH-butyrate:
-
β-hydroxy-butyrate
- IDDM:
-
insulin-dependent diabetes mellitus
- NIDDM:
-
non-insulin-dependent diabetes mellitus
References
Bolli GB (1989) The pharmacokinetic basis of insulin therapy. Diab Res Clin Pract 6: S3-S16
Bolli G, Dimitriadis G, Pehling G et al. (1984) Abnormal glucose counterregulation after subcutaneous insulin in insulindependent diabetes mellitus. N Engl J Med 310: 1706–1711
Binder C, Lauritzen T, Faber O, Pramming S (1984) Insulin pharmakokinetics. Diabetes Care 7: 188–199
Dimitriadis G, Gerich J (1985) Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 6: 374–377
Brange J, Ribel U, Hansen J et al. (1988) Monomeric insulins obtained by protein engineering and their medical implications. Nature (Lond) 333: 679–682
Brange J, Owens D, Kang S, Volund A (1990) Monomeric insulins and their experimental and clinical implications. Diabetes Care 13: 923–954
Frank BH, Brems DN, Chance RE, Di Marchi RD, Shields JE (1991) Manipulation of proline in the B-chain produces monomeric insulins. Diabetes 40 [Suppl 1]: 423 A (Abstract)
Howey DC, Bowsher RR, Brunelle RL, Woodworth JR (1994) [Lys (B28), Pro (B29)]-Human Insulin. A rapidly absorbed analogue of human insulin. Diabetes 43: 396–402
Ter Braak EW, Bianchi R, Erkelens DW (1993) Faster, shorter and more profound action of Lys(B28), Pro(B29) human insulin analogue compared to regular insulin irrespective of the injection site. Diabetes 42 [Suppl 1]: 207 A (Abstract)
Slieker LJ, Sundell K (1991) Modifications in the 28–29 position of the insulin B-chain alter binding to the IGF-I receptor with minimal effect on insulin receptor binding. Diabetes 40 [Suppl 1]: 168 A (Abstract)
Woodworth JR, Bowsher RR, Howey DC, Rowe HM, Ferguson AL (1992) Pharmacokinetic and pharmacodynamic comparison of [Lys B28, Pro B29] human insulin to Humulin R. Pharm Res 9 [Suppl 10]: S292
Woodworth J, Howey D, Bowsher R, Lutz S, Santa P, Brady P (1993) [Lys(B28), Pro(B29)] Human insulin: dose-ranging vs Humulin R. Diabetes 42 [Suppl 1]: 54A (Abstract)
Tuominen JA, Karonen S-L, Koivisto VA (1993) Hypoglycemic effect of short-acting insulin analogue during exercise in type 1 diabetes. Diabetologia 36 [Suppl 1]: A156 (Abstract)
Howey DC, Rowe H, Brunelle R, Downing-Shelton J (1993) [Lys(B28), Pro(B29)] Human insulin: effect of injection time on glucose control. Diabetes 42 [Suppl 1]: 80A (Abstract)
Trautmann ME, Attanasio A, Schulze-Schleppinghoff B, Stiller R, Niederreiter B, Haslbeck M (1993) Blood sugar control during treatment with an insulin analogue. Diabetologia 36 [Suppl 1]: A155 (Abstract)
Ewing DJ, Clarke BF (1982) Diagnosis and management of diabetic autonomic neuropathy. BMJ 285: 916–918
De Feo P, Perriello G, Ventura MM et al. (1986) Studies on overnight insulin requirements and metabolic clearance rate of insulin in normal and diabetic man: relevance to the pathogenesis of the dawn phenomenon. Diabetologia 29: 475–480
McGuire E, Helderman J, Tobin R, Andres R, Berman M (1976) Effects of arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol 41: 565–573
Mitrakou A, Ryan C, Veneman T et al. (1991) Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol 260:E67-E74
Schwartz N, Clutter W, Shah S, Cryer P (1987) Glycemic thresholds for activation of glucose counterregulatory systems are higher than the thresholds for symptoms. J Clin Invest 79: 777–781
Fanelli C, De Feo P, Porcellati F et al. (1992) Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. J Clin Invest 89: 2005–2013
Rizza R, Cryer P, Gerich J (1979) Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation: effects of somatostatin and combined α- and βadrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest 64: 62–71
Lowry O, Passonneau J (1972) Typical fluorimetric procedures for metabolite assays. In: Lowry O, Passonneau J (eds) A flexible system for enzymatic analysis. Academic Press, New York, pp 89–92
De Bodo R, Steele R, Altzuler A, Dunn A, Bishop J (1963) On the hormonal regulation of carbohydrate metabolism: studies with 14C glucose. Recent Prog Horm Res 19: 445–448
Miles J, Haymond M, Gerich J (1982) Effects of free fatty acids, insulin, glucagon, and adrenaline on ketone body production in humans. In: Metabolic acidosis. Ciba Foundation 87, Pitman Books, London pp 192–213
Zar J (1984) Biostatistical analysis. Englewood Cliffs, Prentice Hall
Gottesman I, Mandarino L, Gerich J (1984) Use of glucose uptake and glucose clearance for the evaluation of insulin action in vivo. Diabetes 33: 184–191
Yki-Jarvinen H, Koivisto V (1986) Natural course of insulin resistance in type 1 diabetes. N Engl J Med 315: 224–230
Bolli GB, Gottesman I, Campbell P, Haymond M, Cryer P, Gerich J (1984) Glucose counterregulation and waning of insulin in the Somogyi phenomenon (post-hypoglycemic hyperglycemia). N Engl J Med 311: 1214–1219
Bolli GB, Perriello G, Fanelli C, De Feo P (1993) Nocturnal blood glucose control in type 1 diabetes mellitus. Diabetes Care 16 [Suppl 3]: 71–89
Bruce D, Chisolm D, Storlien L, Kraegen E (1988) Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 37: 736–744
Vignati L, Anderson J, Brunelle R (1994) Efficacy of Lys(B28), Pro(B29) human insulin in a one year global randomized clinical trial. Diabetes 43 [Suppl 1]: Abstract (in press)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Torlone, E., Fanelli, C., Rambotti, A.M. et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. Diabetologia 37, 713–720 (1994). https://doi.org/10.1007/BF00417697
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00417697